{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:50:09Z","timestamp":1788922209587,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["JUST-2017-AG-DRUG"],"award-info":[{"award-number":["JUST-2017-AG-DRUG"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["806996-JUSTSO"],"award-info":[{"award-number":["806996-JUSTSO"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.pbb.2025.174060","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T20:33:05Z","timestamp":1751661185000},"page":"174060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The novel synthesized naltrexone-related MOR antagonist AT-99 counteracts dopamine releasing and behavioral depressant morphine-induced effects"],"prefix":"10.1016","volume":"255","author":[{"given":"Rafaela","family":"Mostallino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Caria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gessica","family":"Piras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasija","family":"Ture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksims","family":"Vanejevs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Laus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Tocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Di Chiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Paola","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2025.174060_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000433579","article-title":"Efficacy of medications approved for the treatment of alcohol dependence and alcohol withdrawal syndrome in female patients: a descriptive review","volume":"22","author":"Agabio","year":"2016","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.pbb.2025.174060_bb0010","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00213-014-3719-7","article-title":"Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats","volume":"232","author":"Altarifi","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2025.174060_bb2000","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2025.174060_bb0020","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(16)00161-6","article-title":"Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study","volume":"387","author":"Berterame","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2025.174060_bb0025","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0896-6273(00)80082-3","article-title":"A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine","volume":"16","author":"Bonci","year":"1996","journal-title":"Neuron"},{"key":"10.1016\/j.pbb.2025.174060_bb0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0028-3908(85)90072-3","article-title":"The use of quaternary narcotic antagonists in opiate research","volume":"24","author":"Brown","year":"1985","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2025.174060_bb0035","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0306-4522(98)00466-7","article-title":"Reciprocal changes in dopamine responsiveness in the nucleus accumbens shell and core and in the dorsal caudate-putamen in rats sensitized to morphine","volume":"90","author":"Cadoni","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2025.174060_bb0040","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.pbb.2025.174060_bb0045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0026-895X(25)13175-1","article-title":"Molecular cloning and functional expression of a mu-opioid receptor from rat brain","volume":"44","author":"Chen","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174060_bb0050","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174060_bb0055","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0022-3565(25)10630-7","article-title":"Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception","volume":"274","author":"Codd","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.174060_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173157","article-title":"Samidorphan, an opioid receptor antagonist, attenuates drug-induced increases in extracellular dopamine concentrations and drug self-administration in male Wistar rats","volume":"204","author":"Cunningham","year":"2021","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2025.174060_bb0065","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00213-011-2220-9","article-title":"Influence of morphine sensitization on the responsiveness of mesolimbic and mesocortical dopamine transmission to appetitive and aversive gustatory stimuli","volume":"216","author":"De Luca","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2025.174060_bb0070","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.neuropharm.2015.11.017","article-title":"Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE\/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135","volume":"105","author":"De Luca","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2025.174060_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109263","article-title":"Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent \u03bc-opioid receptor agonists","volume":"221","author":"De Luca","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2025.174060_bb0080","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","article-title":"Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats","volume":"85","author":"Di Chiara","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbb.2025.174060_bb0085","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0006-8993(98)00371-0","article-title":"Effect of naloxone on morphine-induced changes in striatal dopamine metabolism and glutamate, ascorbic acid and uric acid release in freely moving rats","volume":"797","author":"Enrico","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.pbb.2025.174060_bb0090","author":"European Union Drugs Agency, EUDA"},{"key":"10.1016\/j.pbb.2025.174060_bb0095","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1126\/science.1335167","article-title":"Cloning of a delta opioid receptor by functional expression","volume":"258","author":"Evans","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.pbb.2025.174060_bb0100","author":"Federal Register"},{"key":"10.1016\/j.pbb.2025.174060_bb0105","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1021\/acs.jcim.9b00843","article-title":"Exploring ligand stability in protein crystal structures using binding pose metadynamics","volume":"60","author":"Fusani","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.pbb.2025.174060_bb0110","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Vivitrex study group: efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2025.174060_bb0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0006-8993(01)03105-5","article-title":"Decrease in basal dopamine levels in the nucleus accumbens shell during daily drug-seeking behaviour in rats","volume":"924","author":"Gerrits","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.pbb.2025.174060_bb0120","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1476-5381.1982.tb09319.x","article-title":"Spectrum of the mu, delta- and kappa-binding sites in homogenates of rat brain","volume":"77","author":"Gillan","year":"1982","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174060_bb0125","author":"go.nature.com\/45j6av4"},{"key":"10.1016\/j.pbb.2025.174060_bb0130","series-title":"Nucleus Accumbens Sub-regions Experience Distinct Dopamine Release Responses Following Acute and Chronic Morphine Exposure. bioRxiv 2024.06.28.601282","author":"Gooding","year":"2024"},{"key":"10.1016\/j.pbb.2025.174060_bb0135","first-page":"2012","article-title":"FDA approves nalmefene, a longer-lasting opioid reversal nasal spray","volume":"329","author":"Harris","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2025.174060_bb0140","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1523\/JNEUROSCI.0820-14.2015","article-title":"Opioid receptor-dependent sex differences in synaptic plasticity in the hippocampal mossy fiber pathway of the adult rat","volume":"35","author":"Harte-Hargrove","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2025.174060_bb0145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.36076\/ppj.2008\/11\/225","article-title":"Opioid antagonists, partial agonists, and agonists\/antagonists: the role of office-based detoxification","volume":"11","author":"Helm","year":"2008","journal-title":"Pain Physician"},{"key":"10.1016\/j.pbb.2025.174060_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106105","article-title":"Leveraging black-market street buprenorphine pricing to increase capacity to treat opioid addiction, 2010-2018","volume":"137","author":"Hswen","year":"2020","journal-title":"Prev. Med."},{"key":"10.1016\/j.pbb.2025.174060_bb0160","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.3390\/ijms24043351","article-title":"Inhibitory effects of a novel \u03bc-opioid receptor nonpeptide antagonist, UD-030, on morphine-induced conditioned place preference","volume":"24","author":"Ide","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pbb.2025.174060_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.79","article-title":"Naltrexone modulates dopamine release following chronic, but not acute amphetamine administration: a translational study","volume":"7","author":"Jayaram-Lindstr\u00f6m","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2025.174060_bb0170","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1001\/jama.2018.2844","article-title":"Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016","volume":"319","author":"Jones","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2025.174060_bb0175","first-page":"48","article-title":"The potential of methocinnamox as a future treatment for opioid use disorder: a narrative review","volume":"10","author":"Jordan","year":"2022","journal-title":"Pharmacy (Basel)"},{"key":"10.1016\/j.pbb.2025.174060_bb0180","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/YCO.0000000000000712","article-title":"The opioid overdose crisis as a global health challenge","volume":"34","author":"Krausz","year":"2021","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.pbb.2025.174060_bb0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00213-007-0815-y","article-title":"Reciprocal effects of response contingent and noncontingent intravenous heroin on in vivo nucleus accumbens shell versus core dopamine in the rat: a repeated sampling microdialysis study","volume":"194","author":"Lecca","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2025.174060_bb0190","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/npp.2010.190","article-title":"Effects of drugs of abuse on putative rostromedial tegmental neurons, inhibitory afferents to midbrain dopamine cells","volume":"36","author":"Lecca","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2025.174060_bb0195","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1021\/jm801272c","article-title":"Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists","volume":"52","author":"Li","year":"2009","journal-title":"J. Med. Chem."},{"issue":"sup2","key":"10.1016\/j.pbb.2025.174060_bb0200","first-page":"1","article-title":"Differences in naloxone dosing by gender in emergency department opioid overdose: results of a multicenter study. Clinical Toxicology 61:44\u201345. North American Congress of Clinical Toxicology (NACCT) 2023","volume":"61","author":"Love","year":"2023","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.pbb.2025.174060_bb0205","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2014","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pbb.2025.174060_bb0210","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0278-5846(00)00119-6","article-title":"Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain","volume":"24","author":"Melis","year":"2000","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2025.174060_bb0215","doi-asserted-by":"crossref","first-page":"16120","DOI":"10.1523\/JNEUROSCI.1572-12.2012","article-title":"Morphine withdrawal enhances constitutive \u03bc-opioid receptor activity in the ventral tegmental area","volume":"32","author":"Meye","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2025.174060_bb0220","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-5793(93)80240-U","article-title":"Cloning and expression of a cDNA for the rat kappa-opioid receptor","volume":"329","author":"Minami","year":"1993","journal-title":"FEBS Lett."},{"key":"10.1016\/j.pbb.2025.174060_bb0225","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/10550490290087929","article-title":"Naltrexone and dysphoria: fact or myth?","volume":"11","author":"Miotto","year":"2002","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.pbb.2025.174060_bb0230","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1124\/dmd.111.038588","article-title":"Preclinical disposition (in vitro) of novel \u03bc-opioid receptor selective antagonists","volume":"39","author":"Mitra","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.pbb.2025.174060_bb0235","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.neuropharm.2019.03.020","article-title":"Role of agonist efficacy in exposure-induced enhancement of mu opioid reward in rats","volume":"151","author":"Moerke","year":"2019","journal-title":"Neuropharmacology"},{"issue":"827","key":"10.1016\/j.pbb.2025.174060_bb1000","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejphar.2018.03.013","article-title":"In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14\u03b2-dihydroxy-4,5\u03b1-epoxy-6\u03b1-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator","volume":"15","author":"Obeng","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174060_bb0240","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/00952997509005662","article-title":"Clinical experience with naltrexone","volume":"2","author":"O\u2019Brien","year":"1975","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.pbb.2025.174060_bb0245","doi-asserted-by":"crossref","first-page":"897","DOI":"10.15585\/mmwr.mm6634a2","article-title":"Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region - United States, 2006-2015","volume":"66","author":"O\u2019Donnell","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.pbb.2025.174060_bb0250","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.15585\/mmwr.mm6643e1","article-title":"Deaths involving fentanyl, fentanyl analogs, and U-47700 - 10 states, July-December 2016","volume":"66","author":"O\u2019Donnell","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.pbb.2025.174060_bb0255","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1021\/acs.jmedchem.2c00087","article-title":"Design, synthesis, and biological evaluation of NAP Isosteres: a switch from peripheral to central nervous system acting Mu-opioid receptor antagonists","volume":"65","author":"Pagare","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2025.174060_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.107023","article-title":"IUPHAR review: recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders","volume":"199","author":"Pagare","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pbb.2025.174060_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28795","article-title":"Fentanyl and its derivatives: pain-killers or man-killers?","volume":"10","author":"Patocka","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.pbb.2025.174060_bb0270","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bbr.2010.08.005","article-title":"Naloxone blocks ethanol-mediated appetitive conditioning and locomotor activation in adolescent rats","volume":"216","author":"Pautassi","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2025.174060_bb0275","series-title":"The Rat Brain in Stereotaxic Coordinates","year":"1998"},{"key":"10.1016\/j.pbb.2025.174060_bb0280","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1111\/bph.15494","article-title":"Repeated exposure to JWH-018 induces adaptive changes in the mesolimbic and mesocortical dopaminergic pathways, glial cells alterations, and behavioural correlates","volume":"178","author":"Pintori","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174060_bb0285","doi-asserted-by":"crossref","first-page":"12304","DOI":"10.1073\/pnas.92.26.12304","article-title":"Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the \u201cshell\u201d as compared with the \u201ccore\u201d of the rat nucleus accumbens","volume":"92","author":"Pontieri","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbb.2025.174060_bb0290","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2016.08.032","article-title":"In vitro and in vivo pharmacological characterization of SSD114, a novel GABAB positive allosteric modulator","volume":"791","author":"Porcu","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174060_bb0295","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/0006-8993(91)91724-F","article-title":"Dopamine microdialysis in the nucleus accumbens during acute and chronic morphine, naloxone-precipitated withdrawal and clonidine treatment","volume":"566","author":"Pothos","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.pbb.2025.174060_bb0300","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/ADM.0000000000000324","article-title":"Misuse of novel synthetic opioids: a deadly new trend","volume":"11","author":"Prekupec","year":"2017","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.pbb.2025.174060_bb0305","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0006-8993(91)91616-9","article-title":"Microdialysis evidence that acetylcholine in the nucleus accumbens is involved in morphine withdrawal and its treatment with clonidine","volume":"561","author":"Rada","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.pbb.2025.174060_bb0310","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1046\/j.1440-1614.2002.01012.x","article-title":"Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose","volume":"36","author":"Ritter","year":"2002","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.pbb.2025.174060_bb0315","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.fsisyn.2019.09.003","article-title":"The hidden costs of the opioid crisis and the implications for financial management in the public sector","volume":"1","author":"Ropero-Miller","year":"2019","journal-title":"Forensic Sci. Int. Synerg."},{"key":"10.1016\/j.pbb.2025.174060_bb0320","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF02249408","article-title":"Different behavioral effects of haloperidol, clozapine and thioridazine in a concurrent lever pressing and feeding procedure","volume":"125","author":"Salamone","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2025.174060_bb0325","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0022-3565(24)37462-2","article-title":"Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus","volume":"285","author":"Selley","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.174060_bb0330","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/00001756-199308000-00012","article-title":"In vivo monoamine release during naloxone-precipitated morphine withdrawal","volume":"4","author":"Silverstone","year":"1993","journal-title":"Neuroreport"},{"key":"10.1016\/j.pbb.2025.174060_bb0335","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0014-2999(96)00211-7","article-title":"Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum","volume":"307","author":"Sim","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174060_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108019","article-title":"Treatment of overdose in the synthetic opioid era","volume":"233","author":"Skolnick","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pbb.2025.174060_bb0345","series-title":"The Treatment of Opioid Dependence","author":"Strain","year":"2005"},{"key":"10.1016\/j.pbb.2025.174060_bb0350","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1126\/science.276.5321.2048","article-title":"Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism","volume":"276","author":"Tanda","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.pbb.2025.174060_bb0355","series-title":"StatPearls","article-title":"Opioid antagonists","author":"Theriot","year":"2025"},{"key":"10.1016\/j.pbb.2025.174060_bb0360","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200432","article-title":"3-[3-(Phenalkylamino)cyclohexyl]phenols: synthesis, biological activity, and in silico investigation of a naltrexone-derived novel class of MOR-antagonists","volume":"356","author":"Tocco","year":"2023","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.pbb.2025.174060_bb0365","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14740338.6.2.125","article-title":"Naloxone treatment in opioid addiction: the risks and benefits","volume":"6","author":"van Dorp","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.pbb.2025.174060_bb0370","doi-asserted-by":"crossref","first-page":"6736","DOI":"10.1073\/pnas.90.14.6736","article-title":"Cloning and functional comparison of kappa and delta opioid receptors from mouse brain","volume":"90","author":"Yasuda","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbb.2025.174060_bb0375","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0028-3908(88)90141-4","article-title":"Comparative binding of mu and delta selective ligands in whole brain and pons\/medulla homogenates from rat: affinity profiles of fentanyl derivatives","volume":"27","author":"Yeadon","year":"1988","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2025.174060_bb0380","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0306-4522(99)00046-9","article-title":"Fentanyl increases dopamine release in rat nucleus accumbens: involvement of mesolimbic mu- and delta-2-opioid receptors","volume":"92","author":"Yoshida","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2025.174060_bb0385","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.1016\/j.bmc.2013.08.042","volume":"21","author":"Zaidi","year":"2013","journal-title":"Bioorg. Med. Chem."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305725001078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305725001078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T13:30:05Z","timestamp":1777123805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305725001078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":77,"alternative-id":["S0091305725001078"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2025.174060","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The novel synthesized naltrexone-related MOR antagonist AT-99 counteracts dopamine releasing and behavioral depressant morphine-induced effects","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2025.174060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"174060"}}